EXPLORE THE SCIENCE
Alzheimer’s Treatment Needs More Than Amyloid TL;DR: A 2026 review in Science China Life Sciences argues that amyloid-beta antibodies such as lecanemab and donanemab are important progress, but Alzheimer’s treatment cannot stop at amyloid. The disease also inv…
Read article
Alpha-Synuclein Testing Could Clarify Dementia Diagnosis TL;DR: In 398 memory-clinic patients, alpha-synuclein seed testing identified Lewy body dementia with 95% sensitivity and revealed hidden synuclein positivity in 15.8% of Alzheimer’s disease cases. Key F…
Read article
Broken Blood Vessels May Drive Alzheimer’s Decline TL;DR: A new study reveals that impaired cerebrovascular function—the brain’s ability to regulate blood flow—correlates strongly with Alzheimer’s symptoms, offering a potential non-invasive way to detect early…
Read article
How Lecanemab Clears Brain Amyloid: The Microglia Key TL;DR: Lecanemab, the first Alzheimer’s antibody to slow cognitive decline, works by activating immune cells called microglia through a specific immune signaling pathway, with the molecule SPP1/osteopontin…
Read article
Cell-Type Gene Networks Reveal Hidden Causes of Alzheimer’s TL;DR: Researchers mapped how genes are regulated differently across six brain cell types in Alzheimer’s disease, discovering that excitatory neurons drive the most extensive regulatory disruptions—an…
Read article
The Death Complex Fueling Alzheimer’s (And How to Stop It) TL;DR: Researchers discovered a toxic interaction between two brain proteins—NMDAR and TRPM4—that drives neurodegeneration in Alzheimer’s disease, and a small molecule called FP802 that blocks this “de…
Read article
Dirty Air, Fragile Brain: PM2.5’s Direct Link to Alzheimer’s TL;DR: A massive study of 27.8 million Medicare beneficiaries found that exposure to fine air pollution (PM2.5) increases Alzheimer’s risk by 8.5% per unit increase—and this effect operates largely t…
Read article
Blood Test Detects Alzheimer’s with 83% Accuracy TL;DR: A new blood test using three misfolded plasma proteins can identify Alzheimer’s disease with 83.44% accuracy, outperforming conventional biomarkers and offering a non-invasive screening tool years before…
Read article
Omega-3 supplements and Souvenaid® show potential in slowing cognitive decline in Alzheimer’s patients, though the evidence remains inconclusive. Highlights: Cognitive Decline Reduction: The CDR scale showed a significant reduction in cognitive decline progres…
Read article
ACOT7 shows promise as a non-invasive serum biomarker for Alzheimer’s disease (AD) with high diagnostic accuracy. Highlights: Increased Expression: ACOT7 levels were significantly elevated in AD patients and animal models compared to controls. Correlation with…
Read article